Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests

Taegyu Kim, MD,* Bong-Wan Kim, MD, PhD,* Hee-Jung Wang, MD, PhD,* Hyun Young Lee, PhD,† Je Hwan Won, MD, PhD,‡ Jinoo Kim, MD, PhD,† Xu-Guang Hu, MD,‡ Joohyun Sim, MD, Jun Bae Bang, MD,‡ and Young Bae Kim, MD, PhD§

INTRODUCTION

Hepatic resection (HR) still stays as one of the main treatment modalities for the hepatocellular carcinoma (HCC) with or without liver cirrhosis. However, HR should be carefully selected among the patients with well-preserved liver function to avoid the postoperative complications related to liver failure. Also, well-preserved or compensated liver function has been defined by the absence of clinically relevant portal hypertension (PHT). Liver transplantation or nonsurgical treatments are recommended for the HCC patients with the evidence of PHT, rather than HR. The clinical evidence of PHT could be evaluated by various methods, such as hepatic venous pressure gradient (HVPG), dye-retention test, Child-Pugh scoring system, serum routine chemistry, and platelet counts.

Measuring HVPG has been known as the most reliable clinical method to estimate portal pressure, and HVPG exceeding 10 mm Hg is defined as decompensated PHT and associated with increased cirrhosis-related complications.1,2 Previous studies reported that HR for the patients with HVPG over 10 mm Hg is associated with serious postoperative complications of liver failure and mortality.3,4 Barcelona-Clinic Liver Cancer group treatment guideline for HCC recommended liver transplantation or nonsurgical modality for the patients with high HVPG ≥ 10 mm Hg.5,6 However, the measurement of HVPG has not been preferred in Asian countries because it requires more complicated procedures than other methods. Required procedures such as puncture of central vein and catheter insertion into vena cava may cause possible complications of bleeding, soft tissue hematoma, nerve injury, or arrhythmia.7,8

In the East Asian countries like Korea and Japan, the indocyanine green retention test (ICG-R15) has been commonly used for the surgical patients to determine PHT, and extent of hepatocellular carcinoma, liver function tests, portal hypertension.

Keywords: hepatocarcinoma, hepatic venous pressure gradient, hepatocellular carcinoma, liver function tests, portal hypertension

(Ann Surg 2016;264:330–338)

From the *Department of Liver Transplantation and Hepatobiliary Surgery, Ajou University School of Medicine, Suwon, South Korea; †Department of Biostatistics, Clinical Trial Center, Ajou University School of Medicine, Suwon, South Korea; ‡Department of Radiology, Ajou University School of Medicine, Suwon, South Korea; and §Department of Pathology, Ajou University School of Medicine, Suwon, South Korea.

Authorship contribution: BWK and HJW designed the study, BWK, HJW, HYL, JW, JK, XGH, JS, JBB, and YBK discussed and conducted the study and reviewed the manuscript. TK, BWK, HY, and YBK collected and analyzed the data and wrote the manuscript. The authors declare no conflicts of interest.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Reprints: Bong-Wan Kim, MD, PhD, Department of Hepatobiliary Surgery and Liver Transplantation, Ajou University School of Medicine, San 5, Wonchondong, Youngtong-gu, Suwon 443-749, South Korea. E-mail: dr bwkim@ ajou.ac.kr.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

ISBN: 0003-4932/14/26105-0821 DOI: 10.1097/SLA.0000000000001460

Annals of Surgery • Volume 264, Number 2, August 2016

330 | www.annalsof surgery.com
Authors of this study attempted to establish a reliable equation of calculated HVPG (cHVPG). First, we analyzed the serological tests, which had the significant correlation with measured HVPG and established a model of cHVPG using the values of those serological tests by the linear regression analysis. Then we prospectively assessed the feasibility of cHVPG for the surgical patients with borderline liver reserve.

**PATIENTS AND METHODS**

**Correlation Between Hepatic Venous Pressure Gradient and Serological Tests**

Between January 2006 and December 2008, 171 consecutive patients who underwent the liver surgery in our institute were included to establish the correlation between HVPG and the serological tests (correlation cohort). The patients with obstructive jaundice were excluded in this study. The 171 patients in the correlation cohort underwent preoperative measurements of HVPG, ICG-R15, CBC, and LFT simultaneously within 2 days before the scheduled liver surgery. A regression analysis was performed between the values of 171 patients’ HVPG and the serological tests to establish the equation of cHVPG. All procedures and tests were performed with the informed consent provided to the patients and their legal guardians. The study was conducted after approval of the institutional review board.

The reasons of liver surgery for 171 patients in the correlation cohort were described in Table 1. Among 171 patients, 73 (42.7%) had hepatitis B virus-related liver disease, 6 (3.5%) had alcoholic liver disease, 4 had hepatitis C virus-related liver disease, and 4 had cryptogenic liver cirrhosis. Eighty of 171 (46.8%) patients had biopsy-proven liver cirrhosis. The 171 patients underwent HR in 131, live donor liver transplantation (LDLT) in 38, and abdominal resection in 2 due to peritoneal carcinomatosis. Among 131 patients who underwent HR, 101 (77.1%) underwent major HR (>2 segment resection), and 30 (22.9%) received monosegmentectomy or wedge resection. Liver specimens of 169 patients who received liver surgery were analyzed histologically by a single pathologist (YB Kim). All 171 patients in the correlation cohort recovered from surgery and were discharged uneventfully.

**Preoperative Measurements of Hepatic Venous Pressure Gradient**

After overnight fasting, the patients had been referred to the interventional radiologists (JW Kim and JH Won) who are exclusively responsible for the hepatic hemodynamic intervention. Under the local anesthesia, a 6-french venous introducer was inserted to the right internal jugular vein by the ultrasonography-guided Seldinger technique. A 5-french ballooning catheter with pressure sensor (C2 Cobra catheter; Torcon NB® Advantage catheter, Cook Medical Inc.) was advanced via the introducer into the right hepatic vein under fluoroscopic control. Free hepatic venous pressure (FHVP) was measured after the pressure was stabilized for 1 minute. Then the right hepatic vein was completely occluded by the catheter balloon to measure wedged hepatic venous pressure (WHVP). When the right hepatic vein was compressed or invaded by hepatic malignancy, the middle hepatic vein or the left hepatic vein was chosen for WHVP and FHVP. After 3 sets of measurements, alternating between FHVP and WHVP, the median value was recorded. HVPG was drawn by subtracting FHVP from WHVP.

**Preoperative Measurement of Indocyanine Green-R15 and Laboratory Tests**

A bolus of ICG was injected to the patients kept under overnight fasting with a dose of 0.5 mg/kg via the cephalic vein of 1 forearm. Fifteen minutes after the ICG injection, 8 mL of blood was sampled from the other forearm in a heparinized bottle. The injection of ICG and the blood sampling was exclusively conducted by a single technician (DH Kang). The concentration of ICG in the plasma was determined by the spectrophotometry at 805 nm (Libra S12 spectrophotometer, Bichrom Ltd.). The value of ICG-R15 was expressed as the percentage retention at 15 minutes.

Laboratory tests included CBC, serum electrolytes, serum bilirubin, serum albumin, aspartate transaminase, alanine transaminase, gamma-glutamyl transpeptidase, serum creatinine, and PT-INR. All blood samples for the laboratory tests were drawn after overnight fasting on the same day of ICG-R15 test.

**Clinical Application of Calculated Hepatic Venous Pressure Gradient**

Between January 2009 and December 2013, we applied the cHVPG by the K-equation for determination of PHT in the surgical patients with HCC (application cohort). In this period, the measurement of HVPG was not performed for preoperative evaluation of HCC, and the resectability of HCC was determined by the value of cHVPG by the K-equation, regardless of single value of serological test. The patient with cHVPG < 10 mm Hg was considered as having no PHT and regarded as a candidate of HR but cHVPG ≥ 10 mm Hg was considered as an evidence of PHT and unsuitable for HR. The patients with evident PHT with cHVPG ≥ 10 mm Hg were recommended to perform treatments other than HR such as liver transplantation, local ablation, or transcatheter arterial chemoembolization. To evaluate reliability of the cHVPG for HR, we divided the patients with cHVPG < 10 mm Hg (candidate of HR) into 2 groups by the value of ICG-R15 20%. Among the surgical patients with cHVPG < 10 mm Hg, the patients with ICG-R15 < 20% were regarded as group A and ICG-R15 ≥ 20% as group B. Operative outcomes and postoperative complications of group A and B patients were recorded. The short-term and long-term outcomes of HR in group A and B patients were analyzed and compared to determine the clinical feasibility of cHVPG in the assessment of PHT for surgical patients.

**Statistical Analysis**

Statistical analysis was performed using SPSS statistics 13.0. Data were expressed as mean or median values, ranges, and percentages. Univariate analysis was performed by the Student t test or χ² test. In multivariate analysis, the value of HVPG was correlated to the serological tests using the linear regression analysis. The survival rates were analyzed by the Kaplan-Meier test. P values < 0.05 were regarded as the valid significance in statistics. The value of R², by the regression analysis, determined the reliability of the regression equation. The fitness of the regression model has been validated by the residual plots and analysis of variance (ANOVA) with F-statistics. Sensitivity and specificity for the potential diagnostic performance to predict PHT by cHVPG were assessed by receiver operating characteristic (ROC) curve.

---

**TABLE 1. Causes of Liver Surgery in the Correlation Cohort**

| Diagnosis                   | N/171 (%) |
|-----------------------------|-----------|
| Hepatocellular carcinoma    | 57 (33.3) |
| Living liver donor          | 38 (22.2) |
| End-stage liver cirrhosis   | 29 (16.9) |
| Metastatic liver cancer     | 17 (9.9)  |
| Hepatolithiasis             | 15 (8.8)  |
| Cholangiocarcinoma          | 9 (5.3)   |
| Other*                      | 6 (3.5)   |

*Other: 2 gallbladder cancer, 1 cystic adenoma, 1 hepatic adenoma, 1 benign inflammatory hepatic mass, and 1 chronic cholecystitis.
**RESULTS**

In 171 patients of the correlation cohort, preoperative HVPG and the serological tests were measured without serious complications. However, 3 of 171 (1.8%) developed soft tissue hematoma related with central venous puncture of the right jugular vein. The cervical hematoma was managed conservatively and resolved without sequelae. The patients’ characteristics, measurement of HVPG, the serological tests, and liver histology of the correlation cohort were described in Table 2.

**Correlation of Hepatic Venous Pressure Gradient With Serological Test**

The 171 patients in the correlation cohort showed mean 6.72 ± 5.9 mm Hg of HVPG (range from 0 to 31 mm Hg; 95% confidence interval of 0.8–12.6 mm Hg). Among them, 129 (75%) showed HVPG less than 10 mm Hg, and remaining 42 had HVPG ≥ 10 mm Hg. The 129 patients with HVPG < 10 mm Hg in the correlation cohort received right trisectionectomy in 2, right hemihepatectomy in 30, right anterior or posterior sectionectomy in 32, left hemihepatectomy in 29, left lateral sectionectomy in 8, monosegmentectomy in 10, wedge resection in 12, exploratory laparotomy only in 2, and LDLT in 4. The 42 patients with HVPG ≥ 10 mm Hg underwent LDLT (n = 34), and wedge resection (n = 8). The value of HVPG was significantly correlated with ICG-R15, platelet count, PT-INR, serum total bilirubin, and serum albumin in univariate analysis. Multivariate analysis revealed that the value of ICG-R15, platelet count, PT-INR, and serum albumin were independently correlated to HVPG; however, total bilirubin had no significant correlation (P = 0.652). The histological examination of the surgical specimens showed that only stage IV liver fibrosis was significantly correlated with HVPG ≥ 10 mm Hg (Table 3).

In the correlation cohort, ICG-R15 value was mean 19.7 ± 13.8 with ranged from 3.6% to 65.2%, serum albumin was mean 3.84 ± 0.92 (range from 2.3 to 5.2 g/dL), platelet count was mean 207,098 ± 100,235 per μL (range from 27,000 per to 575,000 per μL), and PT-INR was mean 1.24 ± 0.5 (range from 0.84 to 4.59). The individual correlation of HVPG with ICG-R15, serum albumin, platelet count, and PT-INR by a

---

**TABLE 2. Patients’ Characteristics and Liver Function Tests of the Correlation Cohort**

| Variables       | n = 171 |
|-----------------|---------|
| Age (years)     | 49 (16–84) |
| Male sex        | 119 (69.6%) |
| Weight (kg)     | 64.4 ± 9.9 |
| Height (cm)     | 165.6 ± 7.8 |
| BMI (kg/m²)     | 23.4 (17.1–33.1) |
| HVPG (mm Hg)    | 6.72 ± 5.9 |
| ICG-R15%        | 19.69 ± 13.8 |
| PT-INR          | 1.24 ± 0.5 |
| Platelet count (×10⁴) per μL | 207.1 ± 100 |
| Serum creatinine (mg/dL) | 0.85 ± 0.2 |
| BUN (mg/dL)     | 24.61 ± 17.2 |
| Serum total bilirubin (mg/dL) | 1.83 ± 4.4 |
| Serum AST (U/L) | 43.90 ± 26.7 |
| Serum ALT (U/L) | 44.81 ± 36.1 |
| Serum γ-GT (U/L) | 81.3 ± 34.2 |
| Serum albumin (g/dL) | 3.84 ± 0.6 |
| Liver histology* | 32 (18.9%) |
| Steatosis >10%  | 159 (94.1%)/10 (5.9%) |
| Fibrosis 0, I, II, III/IV† | 89 (52.7%)/80 (47.3%) |

Data are number (%) or mean ± SD or median (range). ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; γ-GT, gamma-glutamyl transpeptidase; ICG-R15%, indocyanine green 15 minutes retention rate; PT-INR, prothrombin time-international normalized ratio.

*Liver histology was reviewed in 169 liver specimens.
†Fibrosis stage: 0, normal; I, portal fibrosis; II, perportal fibrosis; III, septal fibrosis; IV, cirrhosis.

**TABLE 3. Correlation of Hepatic Venous Pressure Gradient With the Patients’ Characteristics and Serological Tests**

| Variables | HVPG < 10 mm Hg (n = 129) | HVPG ≥ 10 mm Hg (n = 42) | Univariate Analysis, P | Multivariate Analysis, P |
|-----------|---------------------------|--------------------------|------------------------|--------------------------|
| Age (years) | 49 (16–84) | 49 (36–69) | 0.281 | — |
| Male sex   | 88 (68.75%) | 31 (72.1%) | 0.551 | — |
| Weight (kg) | 63.62 ± 9.2 | 66.98 ± 9.5 | 0.118 | — |
| Height (cm) | 165.66 ± 7.5 | 166.14 ± 8.7 | 0.767 | — |
| BMI (kg/m²) | 23.1 (17–33) | 24.1 (19.7–32.3) | 0.068 | — |
| ICG-R15%   | 13.93 ± 13.9 | 39.11 ± 15.0 | <0.001 | <0.001 |
| Platelet count (×10⁴) | 241.18 ± 80.7 | 91.89 ± 72.4 | <0.001 | 0.003 |
| PT-INR     | 1.06 ± 0.1 | 1.83 ± 0.7 | <0.001 | 0.014 |
| Serum creatinine (mg/dL) | 0.85 ± 0.1 | 0.83 ± 0.2 | 0.701 | — |
| BUN (mg/dL) | 24.61 ± 17.2 | 26.10 ± 18.0 | 0.003 | 0.652 |
| Serum total bilirubin (mg/dL) | 0.82 ± 0.3 | 5.24 ± 8.4 | 0.032 | 0.332 |
| Serum AST (U/L) | 43.43 ± 26.1 | 45.67 ± 28.9 | 0.367 | — |
| Serum ALT (U/L) | 45.52 ± 34.2 | 42.40 ± 41.8 | 0.277 | — |
| Serum γ-GT (U/L) | 81.30 ± 34.2 | 79.8 ± 39.8 | 0.432 | — |
| Serum albumin (g/dL) | 4.04 ± 0.4 | 3.12 ± 0.5 | <0.001 | 0.004 |
| Liver histology* | 24 (18.9%) | 8 (19%) | 0.797 | — |
| Steatosis >10% | 122 (96.1%)/5 (3.9%) | 37 (88.1%)/5 (11.9%) | 0.070 | — |
| Fibrosis 0, I, II, III/IV† | 89 (70.1%)/58 (29.9%) | 40/42 (100%) | <0.001 | — |

Data are number (%) or mean ± SD or median (range). Significance was defined as P < 0.05.

*Liver histology was reviewed in 169 liver specimens.
†Fibrosis stage: 0, normal; I, portal fibrosis; II, perportal fibrosis; III, septal fibrosis; IV, cirrhosis.
ALT indicates alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; γ-GT, gamma-glutamyl transpeptidase; ICG-R15, indocyanine green 15 minutes retention rate; PT-INR, prothrombin time-international normalized ratio.
The coefficient of determination ($R^2$ value) was expressed for each correlation.

$$HVPG (\text{mm Hg}) = 0.53 \times ICG - R15(\%) - 3.67$$

$(R^2 = 0.656, \ SE^* = 0.03)$

$$HVPG (\text{mm Hg}) = -6.317 \times \text{albumin}(\text{g/dL}) + 30.947$$

$(R^2 = 0.451, \ SE^* = 0.551)$

$$HVPG (\text{mm Hg}) = -0.038 \times \text{platelet counts}(103) + 14.526$$

$(R^2 = 0.416, \ SE^* = 0.004)$

$$HVPG (\text{mm Hg}) = 7.507 \times \text{PT} - \text{INR} - 2.582$$

$(R^2 = 0.415, \ SE^* = 0.704)$

*Standard error of regression coefficient.

The equations showed that ICG-R15 and PT-INR were directly correlated to HVPG but platelet count and serum albumin level were inversely correlated. According to the $R^2$ values of the equations, ICG-R15 had the best reliable correlation with HVPG among the serological tests ($R^2 = 0.656$). ICG-R15 (A) and prothrombin time-international normalized ratio (D) were positively correlated to HVPG ($P < 0.05$), and serum albumin level (B) and platelet count (C) are inversely correlated to HVPG ($P < 0.05$). A total of 95% prediction intervals are shown as dashed lines. Locally weighted scatter plot smooth for each serological test is shown as dotted line.
K-equation of multivariate analysis using significant correlation factors had coefficient of determination (0.707 of adjusted $R^2$ value). The validity of K-equation has been assessed by the residual plots and ANOVA test ($F = 98.278, P < 0.001$). Cross-validation was also performed to estimate model (K-equation) performance. The 10-fold cross-validation performed allowing nonzero intercept term showed 0.661 of $R^2$ value. The correlation plots between HVPG and cHVPG are shown in Figure 2. With the ROC curve for the correlation cohort, cHVPG values were plotted for their ability to predict the patients to be without PHT (HVPG $< 10$ mm Hg). The area under the curve of the ROC curve was 0.96 (95% confidence interval; 0.93–0.99, $P < 0.001$). At the point on the plot where a patient with cHVPG $< 10$ mm Hg, sensitivity was 98.4% and specificity was 76.2%, respectively, for identification of the patients without PHT. Also, the positive predictive value was 92.7% and the negative predictive value was 94.1% to predict the patients to be without PHT. (Fig. 3).

Clinical Application of Calculated Hepatic Venous Pressure Gradient by K-equation

Between January 2009 and December 2013, 510 consecutive HCC patients of the application cohort underwent the surgical evaluation in our institute. Among them, 17 patients were discovered that they had extra-hepatic metastasis of HCC during surgical evaluation, and they were converted to have palliative treatment. Remaining 493 surgical patients with HCC in the application cohort had further evaluation of resectability with the preoperative value of cHVPG. Among them, 452 patients had cHVPG $< 10$ mm Hg and were considered as candidates of HR, and finally 425 received HR and 27 received LDLT. These 27 LDLT patients were excluded from further analysis in the application cohort. Among the 425 patients who received HR, 357 patients had preoperative ICG-R15 $< 20\%$ (group A) and 68 had ICG-R15 $\geq 20\%$ (group B). There was no patient with ICG-R15 $< 20\%$ who had cHVPG of more than 10 mm Hg. The remaining 41 patients, who had preoperative cHVPG $\geq 10$ mm Hg, received nonresective treatments. The 41 patients with cHVPG $\geq 10$ mm Hg showed 13.35 mm Hg of median cHVPG (ranged from 10.17 to 25.29 mm Hg) and 39.8% of median ICG-R15 (ranged from 24.7% to 64.4%). The treatment flow chart of 510 patients in the application cohort was shown in Figure 4.
The preoperative characteristics and operative outcomes of the 425 HR patients were analyzed and compared between group A (n = 357) and group B (n = 68) in Table 4. The mean value of cHVPG of group A patients was 4.76 ± 1.4 and that of group B was 7.80 ± 1.1. The patients’ characteristics showed no statistical difference between 2 groups. The values of serological tests were similar of group A patients was 4.76 ± 1.4 and that of group B was 7.80 ± 1.1. The patients’ characteristics showed no statistical difference between 2 groups. The values of serological tests were similar

| Outcomes | Group A (n = 357) | Group B (n = 68) | P |
|----------|------------------|-----------------|---|
| Preoperative outcomes | | | |
| Age (years) | 53 (26–80) | 55 (29–77) | 0.820 |
| Male sex | 281 (78.7%) | 55 (80.8%) | 0.382 |
| Weight (kg) | 62.2 ± 10.2 | 64.8 ± 9.5 | 0.306 |
| Height (cm) | 167.54 ± 6.2 | 168.44 ± 7.3 | 0.901 |
| BMI (kg/m²) | 23.8 (16.5–31.3) | 24.1 (17.5–33.4) | 0.290 |
| ICG-R15 (%) | 12.9 (1.2–19.8) | 23.65 (20.1–37.7) | <0.001 |
| Platelet count ($\times$1000) | 163.58 ± 65.1 | 140.82 ± 56.0 | 0.245 |
| PT-INR | 1.05 ± 0.1 | 1.07 ± 0.1 | 0.360 |
| Serum creatinine (mg/dL) | 1.08 ± 0.9 | 1.19 ± 1.3 | 0.537 |
| Serum total bilirubin (mg/dL) | 0.78 ± 0.4 | 0.87 ± 0.4 | 0.255 |
| Serum AST (U/L) | 43.85 ± 30.7 | 50.9 ± 37.7 | 0.427 |
| Serum ALT (U/L) | 40.76 ± 31.7 | 51.5 ± 57.2 | 0.188 |
| Serum albumin (g/dL) | 4.18 ± 0.3 | 4.03 ± 0.3 | 0.563 |
| Operative outcomes | | | |
| Tumor size (cm) | 3.5 (0.4–23.0) | 3.4 (1.0–19.0) | 0.557 |
| Tumor number | 1 (1–8) | 1 (1–6) | 0.454 |
| Operation time (minutes) | 173.51 ± 81.9 | 165.04 ± 75.2 | 0.844 |
| Intraoperative blood loss (mL) | 428 ± 105 | 397 ± 153 | 0.341 |
| Major/minor resection* | 194/163 | 32/36 | 0.088 |
| Resection margin <1 cm | 143 (40%) | 26 (38.2%) | 0.927 |
| TNM stage I/II/III | 242 (67.8%)/74 (20.7%)/30 (11%) | 46 (67.6%)/13 (19.1%)/8 (11.8%) | 0.754 |
| Postoperative outcomes | | | |
| Peak creatinine (mg/dL) | 1.15 ± 1.2 | 1.09 ± 0.3 | 0.712 |
| Peak total bilirubin (mg/dL) | 2.26 ± 1.4 | 2.20 ± 0.9 | 0.764 |
| Peak PT-INR | 1.45 ± 0.3 | 1.44 ± 0.3 | 0.848 |
| Lowest albumin (g/dL) | 3.05 ± 0.4 | 2.95 ± 0.3 | 0.178 |
| Lowest platelet count ($\times$1000) | 103.50 ± 42.8 | 101.46 ± 44.6 | 0.749 |
| Complications | | | |
| Postoperative hemorrhage† | 9 (2.5%) | 1 (1.5%) | 0.580 |
| Lung complication‡ | 40 (11.2%) | 8 (11.8%) | 0.959 |
| Prolonged ascites | 18 (4.4%) | 2 (2.9%) | 0.428 |
| Biliary complication** | 11 (3.1%) | 3 (4.4%) | 0.607 |
| Encephalopathy | 0 | 1 (1.5%) | 0.988 |
| Need of dialysis | 0 | 1 (1.5%) | 0.321 |
| In-hospital mortality | 0 | 1 (1.5%) | 0.321 |
| 3-month mortality | 0 | 0 | 0.893 |
| 6-month mortality | 5 (1.4%) | 1 (1.5%) | 0.672 |
| Length of hospital stay (day) | 12 (6–83) | 13 (8–30) | 0.190 |
| Tumor recurrence | 146 (40.9%) | 31 (45.6%) | 0.361 |
| 5-year survival rates (%) | 76.70% | 72.20% | 0.655 |

Data are number (%) or mean ± SD or median (range). Significance was defined as P < 0.05.

*Major resection means resection of two or more segments.

†Biliary complication means bile leakage or bile duct stricture.

‡TNM stage from AJCC 7th edition.

§Postoperative hemorrhage includes wound or intraperitoneal hemorrhage.

‡Lung complication includes pleural effusion or pneumonia.

ALT, alanine transaminase; AST, aspartate transaminase; ICG-R15, indocyanine green 15 minutes retention rate; PT-INR, prothrombin time-international normalized ratio.

The posthepatectomy laboratory findings showed no significant difference between 2 groups in terms of serum bilirubin, PT-INR, serum creatinine, serum albumin, and platelet count. Also, the incidences of surgical complications after HR were similar between 2 groups (P > 0.05). There were 20 patients who drained more than 500 mL of ascites per day after posthepatectomy day 14. They were treated by dietary sodium restriction and diuretics. There was no patient who developed hepatic encephalopathy after HR in the application cohort. There was 1 case of in-hospital mortality among group B patients on posthepatectomy day 29 due to Acinetobacter pneumonia. She was 69 years old and had underlying chronic obstructive pulmonary disease. The length of hospital stay after.
HR was similar between 2 groups. The remaining 424 patients recovered from HR and were discharged with favorable liver function. There was no 3-month mortality among the 424 patients who were discharged from hospital uneventfully. However, 6 patients died within 6 months after HR due to recurrent HCC (n = 3), liver failure (n = 2), or variceal bleeding (n = 1). During median follow-up periods of 22 months after HR, 177 (41.6%) patients experienced HCC recurrence. However, there was no difference in recurrence of HCC, and 5-year survival rates were similar between 2 groups (P > 0.05).

**DISCUSSION**

HR is one of the major curative modalities of treatments for HCC. An extensive resection of liver parenchyme up to 70% of total liver volume could be performed safely in the patients with normal background liver histology. However, HR could be applied to the limited number of HCC patients with compensated or well-preserved liver cirrhosis defined by HVPG less than 10 mm Hg. Many previous studies reported that the value of HVPG 10 mm Hg could be a cut-off value of clinical relevant PHT in chronic liver disease, related to decompensated symptoms of liver cirrhosis. The patients with decompensated liver cirrhosis may also present abnormal values of the serological tests, such as thrombocytopenia, hyperbilirubinemia, and hypoalbuminemia. Multivariate regression analysis of this study showed that the value of HVPG was significantly correlated with ICG-R15, serum albumin, PT-INR, and platelet count. The serum level of total bilirubin had a correlation with HVPG in the univariate analysis (P = 0.003) but had no significance in the multivariate regression (P = 0.65). However, it was difficult to interpret the reason that the serum bilirubin was significant in the univariate analysis only. Bilirubin alone is neither sensitive nor specific for intrinsic liver disease but serves as an indirect measure of the ability of the liver to take up and conjugate bilirubin and to secrete it eventually. This study developed the individual correlation equations between the value of HVPG and the 4 significant serological tests: ICG-R15, serum albumin, PT-INR, and platelet count. The reliability of each equation was determined by R² value and ANOVA test with F-statistics, which would give information about the goodness of fit and statistical significance of our model. Authors of this study have assumed that linear relationship existed about the goodness of fit and statistical significance of our model. The reliability of each equation was determined by R² value and ANOVA test with F-statistics, which would give information about the goodness of fit and statistical significance of our model. The reliability of each equation was determined by R² value and ANOVA test with F-statistics, which would give information about the goodness of fit and statistical significance of our model. The reliability of each equation was determined by R² value and ANOVA test with F-statistics, which would give information about the goodness of fit and statistical significance of our model. The reliability of each equation was determined by R² value and ANOVA test with F-statistics, which would give information about the goodness of fit and statistical significance of our model.
true model of their relationship. However, in this study, there seems to be nonlinear relationship between HVPG and some of serological tests, revealed by the local smoothers, especially in Figure 1C and 1D. We acknowledge that the weak linearity could be a potential limitation of this study.

ICG is a protein-binding anionic organic dye that is selectively taken up by hepatocytes and excreted unchanged via the bile. The removal of ICG reflects the capabilities of the liver to uptake and excrete, which can be extrapolated to reflect hepatocyte blood flow and functional hepatocytes mass. ICG elimination is, by far, the most widely used and published functional assessment of liver reserve worldwide and has also been useful in predicting short-term prognosis in liver transplant patients. Alternatively, ICG-R15 value of 20% was regarded as the cut-off value for clinically relevant PHT, and the value was suggested by clinical experience or recommendation of many centers. ICG-R15 value of 20% was supposed to be equivalent to HVPG of 10 mm Hg. However, the HVPG of 10 mm Hg was quantitatively equivalent to ICG-R15 value of 25.8% by the correlation equation of this study. The difference of cut-off value of ICG-R15 for clinical PHT between the quantitative value of this study and conventional value could have resulted in overestimation of clinical PHT to the patients with ICG-R15 values between 20% and 25.8%. Those patients with ICC could be deprived of the chance to have HR due to overestimated risk of postoperative complication related to liver failure, if the treatment modality for HCC was selected by the result of ICG-R15 test. The quantification of ICG-R15 for PHT in this study may help liver surgeons to assess liver function of surgical patients more precisely and decide the treatment modality more accurately. The serum albumin level, PT-INR, and platelet count were also significantly correlated to HVPG by multivariate analysis. Serum albumin and PT-INR represent synthetic function of the liver, and these have been used in Child-Pugh scoring system for stratification of chronic liver disease. Both serological parameters were produced exclusively by the liver. The serum albumin value of 3.3 g/dL and PT-INR value of 1.67 correspond to HVPG of 10 mm Hg by the individual equations in this study. The values of serum albumin and PT-INR for PHT were similar to the value of decompensated chronic liver disease in Child-Pugh scoring system. Platelet count of 119,000 per μL was correlated to 10 mm Hg of HVPG by the equation, and the value was similar to the results of previous studies. The median body mass index (BMI) of the correlation cohort of this study was 23.4 kg/m², which might be lesser than those of the Western population. However, previous studies from the Western countries reported that the value of ICG-R15 or HVPG had not been significantly affected by BMI. Also, the result of this study was consistent with those of the previous reports. Thus, we consider that the equation of our study could be translated to population with a higher BMI.

We assessed the clinical feasibility of K-equation on a following prospective cohort of 510 surgical patients with HCC. Among the patients in the application cohort of this study, no one with favorable ICG-R15 < 20% showed chVPG ≥ 10 mm Hg according to K-equation. This result could support the reliability of the correlation equation between HVPG and ICG-R15 of the correlation cohort, which suggested that 10 mm Hg of HVPG was equivalent to 25.8% of ICG-R15. Forty-one patients in the Application cohort who showed the unfavorable value of chVPG ≥ 10 mm Hg were recommended to undergo non-HR treatment according to the treatment guideline of the previous study. Our decision to provide nonresective treatments for those patients with chVPG ≥ 10 mm Hg was appropriately supported by their high values of ICG-R15 (median 39.8%, ranged from 24.7% to 64.4%). However, one of the limitations of our study is that clinical validation of K-equation was impossible in the strict sense because data for outcomes of HR for patients with high values of chVPG (≥ 10 mm Hg) could not be collected.

In the application cohort of this study, HR was recommended and performed in patients with chVPG < 10 mm Hg. There were 27 patients who underwent LDLT for HCC even with chVPG < 10 mm Hg. In our institute, LDLT could be performed for HCC patients without vascular invasion or metastasis on the familial support of a live donor. The remaining patients with chVPG < 10 mm Hg who underwent HR could be divided into 2 groups according to ICG-R15 value, either less than 20% (group A, n = 357) or more than or equal to 20% (group B, n = 68). Unless we applied K-equation for chVPG, the patients of group B might have not been recommended for HR because of unfavorable ICG-R15. The Japanese surgical guideline for HCC recommended that the major HR including 2 or more segments should be performed in patients with ICG-R15 less than 20%, and the policy has been accepted widely in many centers. However, in the application cohort in this study, 32 patients (47%) in group B received major HR successfully, and 22 of them underwent more extensive HR than hemihepatectomy on the basis of favorable results of chVPG (< 10 mm Hg). In this study, there was no significant difference in intraoperative outcomes, types of HR, operative complications, and survival rates after HR between group A and B. The successful surgical outcomes of group B patients in the application cohort of this study could imply that the cHVPG by K-equation should be a clinically reliable model to determine whether a surgical patient has preserved liver function or not. This study has drawn that the cHVPG had higher clinical reliability and accuracy than separate use of the serologic tests for assessment of liver reserve function of the surgical patients. Therefore, authors of this study suggested that K-equation for chVPG was well established and its clinical feasibility was assessed by the correlation and the application cohorts in this study. The clinical application of K-equation for chVPG could be useful to determine the evidence of PHT for the surgical patients with HCC. We expect that it is one of the strong merits that the cHVPG can be drawn without invasive procedures.

Assessment of the liver reserve function for the liver surgery using ICG-R15 has been widely performed in the most Eastern centers and some European centers, whereas ICG-R15 test might not be available in many centers in the United States and the West. This could be one of the limitations for wide application of the equation for chVPG because the ICG-R15 is one of the significant variables in the equation. Besides, the value of ICG-R15 might be affected by some conditions such as jaundice and some genetic disorders. Uptake of ICG by hepatocytes is regulated by ATP-independent organic anion-transporting polypeptide (OATP) located at the basolateral membrane of the liver. Bilirubin competes with ICG for hepatocyte uptake via OATP. Thus, the HCC patients with jaundice due to common hepatic duct invasion might have abnormally high value of ICG-R15. Also, the patients with genetic defect in OATP like Rotor syndrome and constitutional ICG excretory defect should have unreliable value of ICG-R15. These conditions would be another limitation in application of the equation for the chVPG, and direct measurement of the HVPG through interventional radiology could be selected to determine PHT for these patients.

In conclusion, the HVPG could be predicted with serological tests by the K-equation. The chVPG by K-equation could provide a more feasible clinical reference to determine evidence of PHT than value of each serological test for the surgical patients with HCC. The authors of this study suggest that clinical application of chVPG could help liver surgeons to assess portal pressure quantitatively and select HR appropriately for the surgical candidates with HCC.
ACKNOWLEDGMENTS

The authors thank Da-Hye Kang for her excellent technical assistance in measurement of ICG-R15.

REFERENCES

1. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–2261.

2. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–488.

3. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018–1022.

4. Boleslawski E, Petnovi G, Truant S, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg. 2012;99:855–863.

5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.

6. Llovet JM, Fuster J, Bruix J, et al. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:115–120.

7. Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: “remixed and revisited.” Hepatology. 2004;39:295–298.

8. Bosch J, Abrahds JS, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–582.

9. Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304.

10. Yamanaka N, Okamoto E, Kuswata K, et al. Multiple regression equation for prediction of posthepatectomy liver failure. Ann Surg. 1984;200:658–663.

11. Miyagawa S, Makuuchi M, Kawasaki S, et al. Criteria for safe hepatic resection. Am J Surg. 1995;169:589–594.

12. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer. 1994;74:2772–2780.

13. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatic carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440.

14. Dunk AA, Jenkins WI, Burroughs AK, et al. The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease. Br J Clin Pharmacol. 1983;16:117–120.

15. Laperche Y, Oudea MC, Lostanlen D. Toxic effects of indocyanine green on rat liver mitochondria. Toxicol Appl Pharmacol. 1977;41:377–387.

16. Poon RT, Fan ST. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg. 2005;12:31–37.

17. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.

18. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.

19. Poon RT, Fan ST, Lo CM, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg. 2002;236:602–611.

20. Ibrahim S, Chen CL, Wang CC, et al. Small remnant liver volume after right lobe living donor hepatectomy. Surgery. 2006;140:749–755.

21. Yigider C, Farges O, Kiamaneshi R, et al. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl. 2003;9:18–25.

22. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–1407.

23. Sanyal AJ, Bosch J, Bili A, et al. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–1728.

24. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.

25. Garcia-Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445–1449.

26. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35.

27. Carletta J. Assessing agreement on classification tasks: the kappa statistic. Comput Lingu. 1996;22:249–254.

28. Stockmann M, Malinowski M, Lock JP, et al. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology. 2009;56:734–738.

29. Suda K, Ohtsuka M, Ambiru S, et al. Risk factors of liver dysfunction after extended hepatic resection in biliary tract malignancies. Am J Surg. 2009;197:752–758.

30. Cha C. Assessment of hepatic function: implications for the surgical patient. In: Jarnagin WR, Belghiti J, Blumgart LH, eds. Blumgart’s Surgery of the Liver, Biliary Tract, and Pancreas. Philadelphia, PA: Elsevier Saunders; 2012:58–64.

31. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698–708.

32. Stockman PR, Hebbard GS, Gibson RN, et al. Percutaneous transhepatic measurement of the pressure gradient between the portal and hepatic veins. Aust N Z J Med. 1993;23:374–380.

33. Eisenbrey JR, Dave JK, Hallordottir VG, et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. Radiology. 2013;268:581–588.

34. Lisotti A, Azzaroli F, Buonfiglioli F, et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology. 2014;59:643–650.

35. Tsien NC, Frampton AE, Habib NA, et al. Surgical treatment for liver cancer. World J Gastroenterol. 2010;16:927–933.

36. Chijiawa K, Watanabe M, Nakano K, et al. Biliary indocyanine green excretion as a predictor of hepatic adenosine triphosphate levels in patients with obstructive jaundice. Am J Surg. 2000;179:161–166.

37. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339:1217–1227.

38. Nambo M, Namihisa T. Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect. J Gastroenterol. 1996;31:228–236.